


# CLAIMS

1. The use of a naphthoquinone derivative having the Formula 1:




wherein,

R represents an OH group, methyl ether, ethyl ether or a similar ether;


R1 represents a methyl, ethyl or similar aliphatic hydrocarbon derivative;

R2 and R3 each independently represent hydrogen or a group selected from:



wherein R5 represents an OH group, methyl ether, ethyl ether or a similar ether and R6 represents a methyl, ethyl or similar aliphatic hydrocarbon derivative;

R4 represents hydrogen or a group selected from:



wherein R7 represents an OH group, methyl ether, ethyl ether or a similar ether and R8 represents a methyl, ethyl or similar aliphatic hydrocarbon derivative;


AMENDED SHEET

Enpfans AMENDED SHEET


29-06-2001

or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for use in a method of treating and/or controlling tuberculosis in a patient caused by *Mycobacterium tuberculosis*.

2. The use according to claim 1 wherein the naphthoquinone derivative of Formula 1 is a compound of Formula 1a or Formula 1b:



Formula 1a



Formula 1b

wherein R and R1 are as defined for Formula 1 in claim 1.

3. The use according to claim 2 wherein R is an OH group.

4. The use according to claim 2 or claim 3 wherein R1 is a CH<sub>3</sub> group.


5. The use according to claim 1 wherein the naphthoquinone derivative of Formula 1 is 5,5' dihydroxy 7,7' binaphthoquinone (diospyrin) or 8-hydroxy-7-methyl-1,4-naphthoquinone (methyljuglone), or a mixture thereof.

AMENDED SHEET

Enfants AMENDED SHEET


29-06-2001

6. A method of treating and/or controlling tuberculosis caused by *Mycobacterium tuberculosis* comprising administering to a patient in need thereof an effective amount of a naphthoquinone derivative having the Formula 1:




wherein,

R represents an OH group, methyl ether, ethyl ether or a similar ether;  
 R1 represents a methyl, ethyl or similar aliphatic hydrocarbon derivative;  
 R2 and R3 each independently represent hydrogen or a group selected from:



wherein R5 represents an OH group, methyl ether, ethyl ether or a similar ether and R6 represents a methyl, ethyl or similar aliphatic hydrocarbon derivative;

R4 represents hydrogen or a group selected from:




wherein R7 represents an OH group, methyl ether, ethyl ether or a similar ether and R8 represents a methyl, ethyl or similar aliphatic hydrocarbon derivative;


AMENDED SHEET

or pharmaceutically acceptable salts thereof.

7. A method according to claim 6 wherein the naphthoquinone derivative of Formula 1 is a compound of Formula 1a or Formula 1b:



Formula 1a



Formula 1b

wherein R and R1 are as defined for Formula 1 in claim 11.

8. A method according to claim 7 wherein R is an OH group.

9. A method according to claim 7 or claim 8 wherein R1 is a CH<sub>3</sub> group.

10. A method according to claim 6 wherein the naphthoquinone derivative of Formula 1 is 5,5' dihydroxy 7,7' binaphthoquinone (diосpyrin) or 5-hydroxy-7-methyl-1,4-naphthoquinone (methyljuglone), or a mixture thereof.

AMENDED SHEET

AMENDED SHEET

Amended Sheet 29-JUN-01 12:08

29-06-2001

~~11. A method according to claim 6 wherein the naphthoquinone derivative of Formula 1 is administered orally, intravenously, intramuscularly or transdermally.~~

add  
A' →

20060707 03:00

AMENDED SHEET

5

AMENDED SHEET  
EPPf00532011 29-JUNE 12-00

29-06-2007